Fibulin-3 as a Biomarker for Pleural Mesothelioma
Authors:
- Kevin HollevoetKHKevin Hollevoet
- Elad SharonESElad Sharon
- 10 January 2013
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (2) , 189-190
Abstract
To the Editor: Pass et al. (Oct. 11 issue)1 report on fibulin-3 as a new soluble biomarker for malignant mesothelioma. The diagnostic accuracy of plasma levels of fibulin-3 in the Detroit and New York cohorts (area under the receiver-operating-characteristic curve [AUC], 0.99) exceeded that of any previously reported marker. In the external validation cohort, however, the diagnostic accuracy surprisingly decreased (AUC, 0.87). This marked decrease was probably due to differences in the study population, although the study showed no association between plasma fibulin-3 levels and common patient characteristics. To fully comprehend the potential and limitations of this new biomarker, researchers . . .Keywords
This publication has 7 references indexed in Scilit:
- Fibulin-3 as a Blood and Effusion Biomarker for Pleural MesotheliomaNew England Journal of Medicine, 2012
- Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-AnalysisJournal of Clinical Oncology, 2012
- The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating FactorChest, 2012
- Detection of integrin-linked kinase in the serum of patients with malignant pleural mesotheliomaThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Glomerular Filtration Rate Is a Confounder for the Measurement of Soluble Mesothelin in SerumClinical Chemistry, 2009
- Soluble Mesothelin–Related Peptides in the Diagnosis of Malignant Pleural MesotheliomaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin LevelsNew England Journal of Medicine, 2005